Top

Published in:

Open Access 01-12-2015 | Research article

Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)

Authors: Aileen Sy, Kieran S. O’Brien, Margaret P. Liu, Puja A. Cuddapah, Nisha R. Acharya, Thomas M. Lietman, Jennifer Rose-Nussbaumer

Published in: BMC Ophthalmology | Issue 1/2015

Abstract

Background

Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in newer therapies.

Methods

An international survey was distributed to dry eye researchers and expert practitioners via an internet survey. The survey data collected were analyzed with descriptive statistics.

Results

One hundred and fifteen respondents completed the survey; of these, 66 % were cornea specialists. The most commonly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluorometholone (FML) 0.1 % (59/99, 60 %), loteprednol etabonate 0.5 % (50/99, 51 %), and autologous serum eye drops (ASD; 48/97, 49 %). The most commonly prescribed non-topical medications included essential fatty acid supplements (72/104, 69 %), low-dose doxycycline (oral; 61/100, 61 %), and flaxseed supplements (32/96, 33 %) as well as punctal plugs (76/102, 75 %). Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %), followed by less than 2 weeks (24/86, 28 %) and with topical CSA between 2 to 8 weeks (45/85, 53 %) followed by 2 to 6 months (24/85, 28 %). The top three signs and symptoms reported to indicate treatment response were, in order, fluorescein staining of the cornea, reduction in foreign body sensation, and reduction in burning sensation.

Conclusion

This survey offers insight into current expert opinion in the treatment of DED. The results of this survey are hypothesis generating and will aid in the design of future clinical studies.

The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:93–107.

Um SB, Kim NH, Lee HK, Song JS, Kim HC. Spatial epidemiology of dry eye disease: findings from South Korea. Int J Health Geogr. 2014;13:31.CrossRefPubMedPubMedCentral

Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, et al. Clinical guidelines for management of dry eye associated with Sjogren disease. Ocul Surf, 2015;13(2):118–32.

Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90–100.CrossRefPubMedPubMedCentral

Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337–42.CrossRefPubMed

Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY. Clinical treatment of dry eye using 0.03 % tacrolimus eye drops. Cornea. 2012;31:945–9.CrossRefPubMed

Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004;88:647–52.CrossRefPubMedPubMedCentral

Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ. Treatment of Sjogren’s syndrome-associated dry eye an evidence-based review. Ophthalmology. 2011;118:1242–52.PubMed

Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–57.CrossRefPubMed

10.

Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107:967–74.CrossRefPubMed

11.

Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631–9.CrossRefPubMed

12.

Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1 % ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112:1790–4.CrossRefPubMed

13.

Su MY, Perry HD, Barsam A, et al. The effect of decreasing the dosage of cyclosporine A 0.05 % on dry eye disease after 1 year of twice-daily therapy. Cornea. 2011;30:1098–104.CrossRefPubMed

14.

Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res. 2012;37:684–8.CrossRefPubMed

15.

Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case–control study. Am J Ophthalmol. 2005;139:242–6.CrossRefPubMed

16.

Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802–6.CrossRefPubMed

17.

Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol. 2014;252:619–26.CrossRefPubMed

18.

Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. The Cochrane database of systematic reviews. 2010(9):CD006775.

19.

Wojtowicz JC, Butovich I, Uchiyama E, Aronowicz J, Agee S, McCulley JP. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea. 2011;30:308–14.CrossRefPubMed

20.

Creuzot C, Passemard M, Viau S, Joffre C, Pouliquen P, Elena PP et al. Improvement of dry eye symptoms with polyunsaturated fatty acids. J Fr Ophtalmol. 2006;29:868–73.CrossRefPubMed

21.

Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, et al. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 2003;22:97–101.CrossRefPubMed

22.

Aragona P, Bucolo C, Spinella R, Giuffrida S, Ferreri G. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren’s syndrome patients. Invest Ophthalmol Vis Sci. 2005;46:4474–9.CrossRefPubMed

23.

Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013;32:44–53.CrossRefPubMedPubMedCentral

24.

Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88–92.CrossRefPubMed

25.

Bartholomew RS, Reid BJ, Cheesbrough MJ, Macdonald M, Galloway NR. Oxytetracycline in the treatment of ocular rosacea: a double-blind trial. Br J Ophthalmol. 1982;66:386–8.CrossRefPubMedPubMedCentral

26.

Seal DV, Wright P, Ficker L, Hagan K, Troski M, Menday P. Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol. 1995;79:42–5.CrossRefPubMedPubMedCentral

27.

Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23:784–92.CrossRefPubMed

28.

Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Diquafosol Ophthalmic Solution Phase 2 Study G. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954–60.CrossRefPubMed

29.

Kamiya K, Nakanishi M, Ishii R, Kobashi H, Sato N, Shimizu K. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye. 2012;26:1363–8.CrossRefPubMedPubMedCentral

30.

Takamura E, Tsubota K, Watanabe H, Ohashi Y. Diquafosol Ophthalmic Solution Phase 3 Study G. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96:1310–5.CrossRefPubMedPubMedCentral

31.

Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05 % eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147:206–13. e3.CrossRefPubMed

32.

Sanz-Marco E, Udaondo P, Garcia-Delpech S, Vazquez A, Diaz-Llopis M. Treatment of refractory dry eye associated with graft versus host disease with 0.03 % tacrolimus eyedrops. J Ocul Pharmacol Ther. 2013;29:776–83.CrossRefPubMedPubMedCentral

33.

Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126:219–25.CrossRefPubMed

34.

de Paiva CS, Schwartz CE, Gjorstrup P, Pflugfelder SC. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye. Cornea. 2012;31:1299–303.CrossRefPubMed

35.

Zapata LF, Agudelo LM, Paulo JD, Pineda R. Sjogren keratoconjunctivitis sicca treated with rituximab. Cornea. 2007;26:886–7.CrossRefPubMed

36.

Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960–8.CrossRefPubMed

37.

Radford CF, Lehmann OJ, Dart JK. Acanthamoeba keratitis: multicentre survey in England 1992–6. National Acanthamoeba Keratitis Study Group. Br J Ophthalmol. 1998;82:1387–92.CrossRefPubMedPubMedCentral

38.

Bacon AS, Frazer DG, Dart JK, Matheson M, Ficker LA, Wright P. A review of 72 consecutive cases of Acanthamoeba keratitis, 1984–1992. Eye (Lond). 1993;7(Pt 6):719–25.CrossRef

39.

Brown S, Navarro Coy N, Pitzalis C, Emery P, Pavitt S, Gray J et al. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogren’s Syndrome. BMC Musculoskelet Disord. 2014;15:21.CrossRefPubMedPubMedCentral

40.

Pillemer SR, Brennan MT, Sankar V, Leakan RA, Smith JA, Grisius M, et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren’s syndrome. Arthritis Rheum. 2004;51:601–4.CrossRefPubMed

41.

Porola P, Straub RH, Virkki LM, Konttinen YT, Nordstrom DC. Failure of oral DHEA treatment to increase local salivary androgen outputs of female patients with Sjogren’s syndrome. Scand J Rheumatol. 2011;40:387–90.CrossRefPubMed

42.

Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146:350–6.CrossRefPubMed

43.

Asbell PA, Spiegel S. Ophthalmologist perceptions regarding treatment of moderate to severe dry eye: results of a physician survey. Trans Am Ophthalmol Soc. 2009;107:205–10.PubMedPubMedCentral

44.

Graham JE, McGilligan VE, Berrar D, Leccisotti A, Moore JE, Bron AJ, et al. Attitudes towards diagnostic tests and therapies for dry eye disease. Ophthalmic Res. 2010;43:11–7.CrossRefPubMed

Title: Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
Authors: Aileen Sy
Kieran S. O’Brien
Margaret P. Liu
Puja A. Cuddapah
Nisha R. Acharya
Thomas M. Lietman
Jennifer Rose-Nussbaumer
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Ophthalmology / Issue 1/2015
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/s12886-015-0122-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Transient traumatic isolated neurogenic ptosis after a mild head trauma: a case report

Factors affecting cataract surgical coverage and outcomes: a retrospective cross-sectional study of eye health systems in sub-Saharan Africa

Transglutaminase binding fusion protein linked to SLPI reduced corneal inflammation and neovascularization

A rare case of primary congenital glaucoma in combination with neurofibromatosis 1: a case report

Systemic amyloidosis with bilateral conjunctival involvement: a case report

Multimodal imaging findings in a case of severe Central Serous Chorioretinopathy in an uncomplicated pregnancy